Adherence to Adjuvant Hormone Therapy with Tamoxifen and Anastrozole using ARMS-12 and MMAS-4
DOI:
https://doi.org/10.32635/2176-9745.RBC.2022v68n2.1960Keywords:
medication adherence, patient compliance, anastrozole/therapeutic use, tamoxifen/therapeutic use, breast neoplasmsAbstract
Introduction: Among breast cancers, approximately 75% of women are hormone receptors-positive, and these are more likely to respond to hormone therapy with anastrozole and tamoxifen. Although effective, they have significant rates of non-adherence. Objective: To evaluate adherence to adjuvant hormone therapy with tamoxifen and anastrozole in patients consulted at the Mastology and Chemotherapy Outpatient Clinic of Hospital Sao Paulo between 2019 and 2020. Method: Cross-sectional study carried out with 102 women between September 2019 and March 2020. Adherence to hormone therapy was evaluated using the Morisky Medication Adherence Scale (MMAS-4) and Adherence to Refills and Medications Scale of 12 items (ARMS-12). Results: The mean age was 61.5 years (59.3-63.6). Among the patients, 27.7% used tamoxifen and 72.3%, anastrozole. 84.4% of them reported discomfort in using the medication, the most frequent were hot flashes (42.2%) and joint pain (55.9%). 79.2% scored the ARMS>12 scale, about 90% of the women scored MMAS-4 up to 2 points, but there was no significant difference between the types of hormones used for adhesion scales (p=0.815 to p=0.489). Conclusion: Adherence to hormone therapy was relatively low, regardless of the hormone used, and these patients may be at risk of inadequate clinical response.
Downloads
References
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2019 [acesso 2020 abr 10]. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288-300. doi: https://doi.org/10.1001/jama.2018.19323 DOI: https://doi.org/10.1001/jama.2018.19323
Hagen KB, Aas T, Kavaløy JT et al. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: a 5-year prospective study. Breast. 2019;44:52-8. doi: https://doi.org/10.1016/j.breast.2019.01.003 DOI: https://doi.org/10.1016/j.breast.2019.01.003
Cheung WY, Lai EC, Ruan JY, et al. Comparative adherence to oral hormonal agents in older women with breast cancer. Breast Cancer Res Treat. 2015;152(2):419-27. doi: https://doi.org/10.1007/s10549-015-3455-7 DOI: https://doi.org/10.1007/s10549-015-3455-7
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97. doi: https://doi.org/10.1056/NEJMra050100 DOI: https://doi.org/10.1056/NEJMra050100
Nguyen TM, La Caze A, Cottrell N. What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol. 2014;77(3):427-45. doi: https://doi.org/10.1111/bcp.12194 DOI: https://doi.org/10.1111/bcp.12194
Murphy CC, Bartholomew LK, Carpentier MY, et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012 Jul;134(2):459-78. doi: https://doi.org/10.1007/s10549-012-2114-5 DOI: https://doi.org/10.1007/s10549-012-2114-5
Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat. 2012;136(2):495-502. doi: https://doi.org/10.1007/s10549-012-2286-z DOI: https://doi.org/10.1007/s10549-012-2286-z
Stahlschmidt R, Ferracini AC, Souza CM, et al. Adherence and quality of life in women with breast cancer being treated with oral hormone therapy. Support Care Cancer. 2019;27(10):3799-3804. doi: https://doi.org/10.1007/s00520-019-04671-x DOI: https://doi.org/10.1007/s00520-019-04671-x
Gökdoğan F, Kes D. Validity and reliability of the Turkish adherence to refills and medications scale. Int J Nurs Pract. 2017;23(5). doi: https://doi.org/10.1111/ijn.12566 DOI: https://doi.org/10.1111/ijn.12566
Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047. doi: https://doi.org/10.1155/2015/217047 DOI: https://doi.org/10.1155/2015/217047
Pourcelot C, Orillard E, Nallet G, et al. Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence. Breast Cancer Res Treat. 2018;169(1):153-62. doi: https://doi.org/10.1007/s10549-018-4676-3 DOI: https://doi.org/10.1007/s10549-018-4676-3
Birand N, Boşnak AS, Diker Ö, et al. The role of the pharmacist in improving medication beliefs and adherence in cancer patients. J Oncol Pharm Pract. 2019;25(8):1916-26. doi: https://doi.org/10.1177/1078155219831377 DOI: https://doi.org/10.1177/1078155219831377
Ali EE, Cheung KL, Lee CP, et al. Prevalence and determinants of adherence to oral adjuvant endocrine therapy among breast cancer patients in Singapore. Asia Pac J Oncol Nurs. 2017;4(4):283-9. doi: https://doi.org/10.4103/2347-5625.212864 DOI: https://doi.org/10.4103/2347-5625.212864
Marques PAC, Pierin AMG. Fatores que influenciam a adesão de pacientes com câncer à terapia antineoplásica oral. Acta Paul Enferm. 2008;21(2):323-9. doi: https://doi.org/10.1590/S0103-21002008000200015 DOI: https://doi.org/10.1590/S0103-21002008000200015
Aguiar KS. Validação de uma versão em português do instrumento Adherence to Refills and Medications Scale (ARMS) para avaliação de adesão ao tratamento com antineoplásicos orais [dissertação na Internet]. Curitiba: Universidade Federal do Paraná; 2019 [acesso 2021 jan 12]. Disponível em: https://hdl.handle.net/1884/60845
Lebrão ML, Laurenti R. Saúde, bem-estar e envelhecimento: o estudo SABE no município de São Paulo. Rev Bras Epidemiol. 2005;8(2):127-41. doi: https://doi.org/10.1590/S1415-790X2005000200005 DOI: https://doi.org/10.1590/S1415-790X2005000200005
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74. doi: https://doi.org/10.1097/00005650-198601000-00007 DOI: https://doi.org/10.1097/00005650-198601000-00007
Kripalani S, Risser J, Gatti ME, et al. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12(1):118-23. doi: https://doi.org/10.1111/j.1524-4733.2008.00400.x DOI: https://doi.org/10.1111/j.1524-4733.2008.00400.x
Park HY, Seo SA, Yoo H, et al. Medication adherence and beliefs about medication in elderly patients living alone with chronic diseases. Patient Prefer Adherence. 2018;12:175-81. doi: https://doi.org/10.2147/PPA.S151263 DOI: https://doi.org/10.2147/PPA.S151263
Sestak I, Smith SG, Howell A, et al. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. Ann Oncol. 2018;29(2):504-9. doi: https://doi.org/10.1093/annonc/mdx713 DOI: https://doi.org/10.1093/annonc/mdx713
Paranjpe R, John G, Trivedi M, et al. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019;174(2):297-305. doi: https://doi.org/10.1007/s10549-018-05073-z DOI: https://doi.org/10.1007/s10549-018-05073-z
Mohamed KEH, Elamin A. Adherence to endocrine therapy and its relation to disease-free survival among breast cancer patients visiting an out-patient clinic at Khartoum Oncology Hospital, Sudan. J Eval Clin Pract. 2020;26(6):1731-43. doi: https://doi.org/10.1111/jep.13373 DOI: https://doi.org/10.1111/jep.13373
Wulaningsih W, Garmo H, Ahlgren J, et al. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. Breast Cancer Res Treat. 2018;172(1):167-77. doi: https://doi.org/10.1007/s10549-018-4890-z DOI: https://doi.org/10.1007/s10549-018-4890-z
Leite FMC, Bubach S, Amorim MHC, et al. Mulheres com diagnóstico de câncer de mama em tratamento com tamoxifeno: perfil sociodemográfico e clínico. Rev Bras Cancerol. 2011;57(1):15-1. doi: https://doi.org/10.32635/2176-9745.RBC.2011v57n1.680 DOI: https://doi.org/10.32635/2176-9745.RBC.2011v57n1.680
Blanchette PS, Lam M, Richard L, et al. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. Breast Cancer Res Treat. 2020;179(1):217-27. doi: https://doi.org/10.1007/s10549-019-05430-6 DOI: https://doi.org/10.1007/s10549-019-05430-6
Tenti S, Correale P, Cheleschi S, et al. Aromatase inhibitors-induced musculoskeletal disorders: current knowledge on clinical and molecular aspects. Int J Mol Sci. 2020;21(16):5625. doi: https://doi.org/10.3390/ijms21165625 DOI: https://doi.org/10.3390/ijms21165625
Berkowitz MJ, Thompson CK, Zibecchi LT, et al. How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support. J Cancer Surviv. 2021;15(1):29-39. doi: https://doi.org/10.1007/s11764-020-00908-5 DOI: https://doi.org/10.1007/s11764-020-00908-5
Verbrugghe M, Verhaeghe S, Decoene E, et al. Factors influencing the process of medication (non-)adherence and (non-)persistence in breast cancer patients with adjuvant antihormonal therapy: a qualitative study. Eur J Cancer Care (Engl). 2017;26(2). doi: https://doi.org/10.1111/ecc.12339 DOI: https://doi.org/10.1111/ecc.12339
Milata JL, Otte JL, Carpenter JS. Oral endocrine therapy nonadherence, adverse effects, decisional support, and decisional needs in women with breast cancer. Cancer Nurs. 2018;41(1):E9-E18. doi: https://doi.org/10.1097/NCC.0000000000000430 DOI: https://doi.org/10.1097/NCC.0000000000000430
Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006;71(1-2):1-9. doi: https://doi.org/10.1159/000100444 DOI: https://doi.org/10.1159/000100444
Banning M. Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl). 2012;21(1):10-9. doi: https://doi.org/10.1111/j.1365-2354.2011.01295.x DOI: https://doi.org/10.1111/j.1365-2354.2011.01295.x
Grunfeld EA, Hunter MS, Sikka P, et al. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59(1):97-102. doi: https://doi.org/10.1016/j.pec.2004.10.005 DOI: https://doi.org/10.1016/j.pec.2004.10.005
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
